Company Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors.

Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.

The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors.

The company was founded in 2009 and is headquartered in Los Altos, California.

RenovoRx, Inc.

Country	United States
Founded	2012
IPO Date	Aug 26, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	8
CEO	Shaun R. Bagai

Contact Details

Address: 333 W. Santa Clara Street, Suite 900 San Jose, California 95110 United States
Phone	408-800-2649
Website	renovorx.com

Stock Details

Ticker Symbol	RNXT
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$9.00
CIK Code	0001574094
CUSIP Number	75989R107
ISIN Number	US75989R1077
Employer ID	27-1448452
SIC Code	2834

Key Executives

Name	Position
Dr. Ramtin Agah M.D.	Founder, Chairman of Board and Chief Medical Officer
Shaun R. Bagai	Chief Executive Officer and Director
Ronald B. Kocak CPA, CGMA	Vice President, Controller and Principal Accounting Officer
Leesa Gentry	Chief Clinical Officer

Latest SEC Filings

Date	Type	Title
Apr 22, 2024	D	Notice of Exempt Offering of Securities
Apr 19, 2024	S-3	Registration statement under Securities Act of 1933
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report
Apr 15, 2024	8-K	Current Report
Apr 12, 2024	S-8	Securities to be offered to employees in employee benefit plans
Apr 9, 2024	8-K	Current Report
Apr 1, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Feb 23, 2024	8-K	Current Report

View All SEC Filings